Longitudinal brain structural changes in preclinical Alzheimer's disease
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Introduction: Brain structural changes in preclinical Alzheimer's disease (AD) are poorly understood. Methods: We compared the changes in cortical thickness in the ADNI cohort during a 2‐year follow‐up between the NIA‐AA preclinical AD stages defined by cerebrospinal fluid (CSF) biomarker levels. We also analyzed the correlation between baseline CSF biomarkers and cortical atrophy rates. Results: At follow‐up, stage 1 subjects showed reduced atrophy rates in medial frontal areas and precuneus compared to stage 0 subjects, whereas stage 2/3 subjects presented accelerated atrophy in medial temporal structures. Low CSF Aβ 1–42 levels were associated with reduced atrophy rates in subjects with normal tau levels and high CSF tau levels with accelerated atrophy only in subjects with low Aβ 1–42 levels. Discussion: Our longitudinal data confirm a biphasic trajectory of changes in brain structure in preclinical AD. These have implications in AD trials, both in patient selection and the use of MRI as a surrogate marker of efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“109 preclinical phase into three stages [1]: subjects with no evidence of AD biomarker alteration or cognitive decline (stage 0), asymptomatic amyloidosis (stage 1), amyloidosis with evidence of neurodegeneration (stage 2), and amyloidosis, neurodegeneration, and subtle cognitive decline (stage 3).”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“The topography of the changes supports the notion that, at a given timepoint, different brain areas can be at different stages [31].”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Within-subject template estimation for unbiased longitudinal image analysis
Reuter, M., Schmansky, N. J., Rosas, H. D., & Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.084 · Cited by 2,356
Neurodegenerative Diseases Target Large-Scale Human Brain Networks
Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L., & Greicius, M. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.024 · Cited by 2,350
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 2×
“The anatomic order for this neocortical spread of tau pathology begins thus in the medial temporal lobe as it has been proposed [13,33,34], in a pattern of atrophy following the tau Braak stages [32].”
BackgroundBuckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 1×
“However, all these regions are part of the default mode network, and amyloid deposition initially starts in this network [39,40].”
BackgroundCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“The unexpected finding of cortical atrophy (without clinical deterioration) seen in previous active (AN1792 trial) [46] and passive (solanezumab [47] and bapineuzumab [48]) immunization trials is better explained if we consider the pathologic thickening associated with brain amyloidosis [11].”
Background
Cited by
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.005 · Cited by 454
Self-citationAPOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Cortical microstructural changes along the Alzheimer’s disease continuum
Montal, V., Vilaplana, E., Alcolea, D., Pegueroles, J., Pasternak, O., González‐Ortiz, S., Clarimón, J., Carmona‐Iragui, M., Illán‐Gala, I., Morenas‐Rodríguez, E., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.013 · Cited by 204
“The finding of increased CTh in relation to brain amyloidosis has already been reported in several different cohorts in familial and sporadic AD in cross-sectional [4,7–10,33] and longitudinal studies [11].”
BackgroundMethodSelf-citationParker, T. D., Slattery, C. F., Zhang, J., Nicholas, J. M., Paterson, R. W., Foulkes, A. J. M., Malone, I. B., Thomas, D. L., Modat, M., Cash, D. M., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.24056 · Cited by 122
“There is evidence from human imaging studies suggesting that apparently paradoxical increases in grey matter volume and cortical thickness may occur in the early stages of AD before a phase of accelerated atrophy (Ch etelat et al., 2010; Fortea et al., 2010, 2011, 2014; Montal et al., 2017; Pegueroles et al., 2017).”
BackgroundDong, J. W., Jelescu, I. O., Ades-Aron, B., Novikov, D. S., Friedman, K., Babb, J. S., Osorio, R. S., Galvin, J. E., Shepherd, T. M., & Fieremans, E. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.009 · Cited by 70
“, 2011), while a longitudinal study showed reduced rates of cortical atrophy in Abi compared to normal aging from Ab (Pegueroles et al., 2017).”
BackgroundChallenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62
Self-citationBrief Mindfulness Meditation Induces Gray Matter Changes in a Brain Hub.
Tang, R., Friston, K. J., & Tang, Y.-Y. (2020) · Neural Plasticity · doi:10.1155/2020/8830005 · Cited by 54
Falgàs, N., Ruiz‐Peris, M., Pérez‐Millan, A., Sala‐Llonch, R., Antonell, A., Balasa, M., Borrego‐Écija, S., Ramos‐Campoy, O., Augé, J. M., Castellví, M., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24925 · Cited by 32
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Metadata
- Authors
- Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D., Carmona‐Iragui, M., Clarimon, J., Blesa, R., Lleó, A., Fortea, J., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-09-28
- Volume
- 13
- Issue
- 5
- Pages
- 499-509
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2526035417
- Cited by
- 109
- References
- 23
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.